title: RTI-177
text: # RTI-177
  
  RTI(-4229)-177 (2β-(3-phenylisoxazol-5-yl)-3β-(4-chlorophenyl)tropane, β-CPPIT) is a synthetic stimulant drug from the phenyltropane family, which acts as a DRI with micromolar affinity for the SERT. RTI-177 has an unusually long duration of action of 20 hours or more, substantially longer than the related compound RTI-336 from which it differs in molecular structure only by the absence of a p-methyl group.
  
  "the nonselective monoamine transporter inhibitor RTI-126 and the DAT-selective inhibitors RTI-150 and RTI-336 both had a faster rate of onset (30 min) and a short duration of action (4h). In contrast, the nonselective monoamine transporter inhibitor RTI-112 had a slower rate of onset (30–60 min) and a longer duration of action (10h). The DAT-selective inhibitors RTI-171 and RTI-177 also had slower rates of onset (30–120 min), but RTI-171 had a short duration of action (2.5 h) while RTI-177 had a very long duration of action (20 h)."
  
  ## Update
  
  Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates.
  
  ## Comparison of six MAT inhibitors
  
  | RTI | X | R | $[^3H]CFT$ | $[^3H]Nisoxetine$ | $[^3H]Paroxetine$ |
  | - | - | - | - | - | - |
  | Coc | — | — | 89.1 | 3298 (1986) | 1045 (45) |
  | 177 | Cl | phenyl | 1.28 | 504 (304) | 2420 (220) |
  | 176 | Me | phenyl | 1.58 | 398 (239) | 5110 (465) |
  | 354 | Me | ethyl | 1.62 | 299 (180) | 6400 (582) |
  | 336 | Cl | p-cresyl | 4.09 | 1714 (1033) | 5741 (522) |
  | 386 | Me | p-anisoyl | 3.93 | 756 (450) | 4027 (380) |
  
  In the Lindsey paper, RTI-177 was wrongly considered to be a dual inhibitor of the NET, although this was later found out to be incorrect.
  
  "In acute toxicity studies in male rats, 3β-(4-chlorophenyl)-2β-[3-(4’-methylphenyl)isoxazol-5-yl]tropane (RTI-336) possessed an LD50 of 180 mg/kg after oral administration, compared with 49 mg/kg for RTI-177 (unpublished results, Howell 2005; Table 9). These results suggested that RTI-336 was a better candidate than RTI-177 for further preclinical development."
  
  Also the potency of the heterocyclic compounds is not as great as would be predicted based on in vitro test results.
  
  